Acute lymphoblastic leukaemia trials in Netherlands

In Netherlands 22 Also abroad 568

20 of 22 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 15 November 2026. Ask the study team whether a trial fits you.

Phase 1/2Taking people
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Where
Utrecht
Age
1 year to 17 years
People
70 worldwide
Run by
Incyte Biosciences International Sàrl
See details and how to joinNCT03934372 · EU 2023-509699-41-00
Phase 3Taking people
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
Where
Utrecht
Age
1 year to 64 years
People
130 worldwide
Run by
Memorial Sloan Kettering Cancer Center
See details and how to joinNCT07223021 · EU 2025-523096-34-00
Phase 1/2Taking people
Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
Where
Utrecht
Age
1 year to 30 years
People
50 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07387926
Phase 2/3Taking people
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
Where
Amsterdam, Nieuwegein, Nijmegen, Rotterdam, Utrecht
Age
12 years and over
People
340 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07570173 · EU 2025-522267-15-00
Phase 1/2Taking people
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Where
Utrecht
Age
6 months to 25 years
People
90 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00
Phase 3Taking people
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
Where
Utrecht
Age
1 year to 64 years
People
750 worldwide
Run by
Charite University, Berlin, Germany
See details and how to joinNCT07476729 · EU 2023-509392-17-00
Phase 3Taking people
Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
Where
Utrecht
Age
1 day to 1 year
People
160 worldwide
Run by
Princess Maxima Center for Pediatric Oncology
See details and how to joinNCT05327894 · EU 2022-502503-30-00
Phase 1/2Active, not recruiting
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Where
Utrecht
Age
30 days and over
People
447 worldwide
Run by
Syndax Pharmaceuticals
See details and how to joinNCT04065399 · EU 2024-513759-34-00
Phase 1/2Not yet taking people in Netherlands
Study of the safety and efficacy of asciminib in pediatric and young adult participants with r/r Ph+ or ABL-class Ph-like ALL
Where
Utrecht
Age
Up to 64 years
People
22 worldwide
Run by
Novartis Pharma AG
See details and how to join2025-522019-40-00
Phase 2Taking people
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
Where
Utrecht
Age
1 year to 17 years
People
100 worldwide
Run by
Pfizer
See details and how to joinNCT05748171 · EU 2023-509810-13-00
Phase 2/3Active, not recruiting
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
Where
Utrecht
Age
1 month to 18 years
People
1,800 worldwide
Run by
St. Anna Kinderkrebsforschung
See details and how to joinNCT01949129 · EU 2024-512657-24-00
Phase 3Taking people
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
Where
Utrecht
Age
0 years to 45 years
People
6,430 worldwide
Run by
Mats Heyman
See details and how to joinNCT04307576 · EU 2022-501050-11-01
Phase 2Not yet taking people in Netherlands
A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL
Where
Rotterdam, Utrecht
People
86 worldwide
Run by
Centre Hospitalier De Versailles
See details and how to join2024-516570-30-00
Phase 1/2Active, not recruiting
Inotuzumab ozogamicin for Acute Lymphoblastic Leukemia
Where
Rotterdam, Utrecht
Age
Up to 17 years
People
142 worldwide
Run by
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
See details and how to join2023-504694-20-00
Phase 3Taking people
Study on chemotherapy and experimental drugs in patients with Philadelphia Chromosome positive and ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia
Where
Utrecht
Age
Up to 64 years
People
87 worldwide
Run by
Universita Degli Studi Di Milano Bicocca
See details and how to join2025-520982-39-00
Phase 2Taking people
International Study for Treatment of High Risk Childhood Relapsed ALL 2010
Where
Utrecht
Age
Up to 17 years
People
250 worldwide
Run by
Charite University, Berlin, Germany
See details and how to joinNCT03590171 · EU 2024-513070-21-00
Phase 1/2Taking people
LUMC-BOB1-B7-TCR.1 in relapsed and refractory B-cell malignancies
Where
Leiden
Age
18 years and over
People
22
Run by
Leids Universitair Medisch Centrum (LUMC)
See details and how to join2024-515900-38-00
Phase 1/2Taking people
HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies
Where
Utrecht
Age
1 year to 21 years
People
26 worldwide
Run by
Princess Maxima Center for Pediatric Oncology
See details and how to joinNCT05658640 · EU 2022-501869-41-00
Phase 1/2Taking people
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Where
Utrecht
Age
1 year to 21 years
People
26 worldwide
Run by
Princess Maxima Center for Pediatric Oncology
See details and how to joinNCT05745714 · EU 2022-501867-42-01
Phase 1/2Taking people
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Where
Utrecht
Age
1 year to 21 years
People
26 worldwide
Run by
Princess Maxima Center for Pediatric Oncology
See details and how to joinNCT05751044 · EU 2022-501866-22-00